

# Derek P Chew

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8901148/publications.pdf>

Version: 2024-02-01

225  
papers

17,166  
citations

36271

51  
h-index

15249

126  
g-index

232  
all docs

232  
docs citations

232  
times ranked

16214  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Surgical and Transcatheter Aortic Valve Replacement on Frailty Score. <i>Heart Lung and Circulation</i> , 2022, 31, 566-574.	0.2	4
2	Accuracy of Highly Limited Echocardiographic Screening Images for Determining a Structurally Normal Heart: The Quick-Six Study. <i>Heart Lung and Circulation</i> , 2022, 31, 462-468.	0.2	2
3	Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2022, 175, 101-113.	2.0	37
4	Cost effectiveness of a 1-hour high-sensitivity troponin-T protocol: An analysis of the RAPID-TnT trial. <i>IJC Heart and Vasculature</i> , 2022, 38, 100933.	0.6	3
5	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). <i>Heart and Vessels</i> , 2022, 37, 1291-1298.	0.5	3
6	Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health. <i>Journal of Mental Health</i> , 2022, 31, 524-533.	1.0	2
7	Implementation and prospective evaluation of the Country Heart Attack Prevention model of care to improve attendance and completion of cardiac rehabilitation for patients with cardiovascular diseases living in rural Australia: a study protocol. <i>BMJ Open</i> , 2022, 12, e054558.	0.8	5
8	Objective risk assessment vs standard care for acute coronary syndromes – The Australian GRACE Risk tool Implementation Study (AGRIS): a process evaluation. <i>BMC Health Services Research</i> , 2022, 22, 380.	0.9	1
9	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. <i>Atherosclerosis</i> , 2022, 346, 68-74.	0.4	7
10	New balance to an old complex problem. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1376-1377.	0.7	0
11	Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial. <i>Circulation</i> , 2022, 145, 1443-1455.	1.6	27
12	Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population. <i>Heart Lung and Circulation</i> , 2022, 31, 1085-1092.	0.2	1
13	Balancing the Risks of Recurrent Ischaemic and Bleeding Events in a Stable Post ACS Population. <i>Heart Lung and Circulation</i> , 2022, , .	0.2	0
14	Comparative overview of ST-elevation myocardial infarction epidemiology, demographics, management, and outcomes in five Asia-Pacific countries: a meta-analysis. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 6-17.	1.8	16
15	Relation of Body Mass Index to Outcomes in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2021, 138, 11-19.	0.7	10
16	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. <i>Critical Care Medicine</i> , 2021, 49, 503-516.	0.4	41
17	2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region. <i>European Cardiology Review</i> , 2021, 16, e02.	0.7	17
18	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2021, 6, 304.	3.0	29

#	ARTICLE	IF	CITATIONS
19	Troponin elevation pattern and subsequent cardiac and non-cardiac outcomes: Implementing the Fourth Universal Definition of Myocardial Infarction and high-sensitivity troponin at a population level. PLoS ONE, 2021, 16, e0248289.	1.1	4
20	Clinical risk prediction models for the prognosis and management of acute coronary syndromes. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 222-228.	1.8	2
21	Predicting Australian Adults at High Risk of Cardiovascular Disease Mortality Using Standard Risk Factors and Machine Learning. International Journal of Environmental Research and Public Health, 2021, 18, 3187.	1.2	13
22	Pharmacotherapy in Stable Coronary Artery Disease: Historical Perspectives and New Insights from the ISCHEMIA Trial. European Cardiology Review, 2021, 16, e04.	0.7	1
23	Applying a framework to assess the impact of cardiovascular outcomes improvement research. Health Research Policy and Systems, 2021, 19, 67.	1.1	3
24	The influence of travelling to hospital by ambulance on reperfusion time and outcomes for patients with STEMI. Medical Journal of Australia, 2021, 214, 377-378.	0.8	5
25	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. European Cardiology Review, 2021, 16, e26.	0.7	7
26	Case report describing balloon dilatation as a treatment for acute intraprosthesis regurgitation immediately following implantation of a SAPIEN <sup>3</sup> transcatheter aortic valve. Clinical Case Reports (discontinued), 2021, 9, e04193.	0.2	0
27	Surgical and percutaneous management of Aboriginal Australians with rheumatic heart disease: Timeliness and concordance between practice and guidelines. International Journal of Cardiology, 2021, 335, 80-84.	0.8	2
28	Classification performance of clinical risk scoring in suspected acute coronary syndrome beyond a rule-out troponin profile. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1038-1047.	0.4	7
29	Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS. Circulation, 2021, 144, 113-125.	1.6	27
30	Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial. ESC Heart Failure, 2021, 8, 4346-4352.	1.4	15
31	Prognostic Implications of High-Sensitivity Troponin T Levels Among Patients Attending Emergency Departments and Evaluated for an Acute Coronary Syndrome. American Journal of Medicine, 2021, 134, 1019-1028.e1.	0.6	2
32	Missed Opportunities to Initiate Oral Anticoagulant in Atrial Fibrillation: Insights from Australian Acute Coronary Syndrome Registries. Heart Lung and Circulation, 2021, 30, 1157-1165.	0.2	2
33	Polygenic risk score and coronary artery disease: A meta-analysis of 979,286 participant data. Atherosclerosis, 2021, 333, 48-55.	0.4	18
34	Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention. PLoS ONE, 2021, 16, e0259148.	1.1	1
35	2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations. European Cardiology Review, 2021, 16, e43.	0.7	5
36	Implementation of more sensitive cardiac troponin T assay in a state-wide health service. International Journal of Cardiology, 2021, 347, 66-72.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Diagnosis and management of acute coronary syndromes. <i>Australian Prescriber</i> , 2021, 44, 180-184.	0.5	1
38	Response by Lambrakis and Chew to Letter Regarding Article, "Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS" <i>Circulation</i> , 2021, 144, e459-e460.	1.6	1
39	Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. <i>European Cardiology Review</i> , 2021, 16, e54.	0.7	10
40	The Impact of Cardiac Rehabilitation and Secondary Prevention Programs on 12-Month Clinical Outcomes: A Linked Data Analysis. <i>Heart Lung and Circulation</i> , 2020, 29, 475-482.	0.2	49
41	Validation of the "Doorbell Test": A Novel Functional Test of Frailty and Clinical Status After Acute Decompensated Heart Failure. <i>Heart Lung and Circulation</i> , 2020, 29, 1054-1062.	0.2	1
42	Is Atrial Fibrillation a Stroke Risk Factor or Risk Marker? An Appraisal Using the Bradford Hill Framework for Causality. <i>Heart Lung and Circulation</i> , 2020, 29, 86-93.	0.2	11
43	Advanced Echocardiographic Imaging for Prediction of SCD in Moderate and Severe LV Systolic Function. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 604-612.	2.3	21
44	Troponin measurements, myocardial infarction diagnoses and outcomes. An analysis of linked data from New South Wales, Australia. <i>Internal Medicine Journal</i> , 2020, 50, 550-555.	0.5	4
45	Effect of Balloon Aortic Valvuloplasty on Mortality in Patients With Severe Aortic Stenosis Prior to Conservative Treatment and Surgical or Transcatheter Aortic Valve Replacement. <i>Heart Lung and Circulation</i> , 2020, 29, 719-728.	0.2	7
46	The Asia-Pacific Society of Cardiology (APSC) Expert Committee Consensus Recommendations for Assessment of Suspected Acute Coronary Syndrome Using High-Sensitivity Cardiac Troponin T in the Emergency Department. <i>Circulation Journal</i> , 2020, 84, 136-143.	0.7	13
47	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1612-1621.	0.4	12
48	Core Outcomes Set for Trials in People With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1622-1635.	0.4	47
49	Quality of Life Changes in Acute Coronary Syndromes Patients: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6889.	1.2	14
50	Mortality at 5 Years Among Very Elderly Patients Undergoing High Sensitivity Troponin T Testing for Suspected Acute Coronary Syndromes. <i>Heart Lung and Circulation</i> , 2020, 29, 1696-1703.	0.2	1
51	Mortality From Bleeding Versus Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 172-174.	1.2	2
52	High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond. <i>Reviews in Cardiovascular Medicine</i> , 2020, 21, 191.	0.5	22
53	Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-Study. <i>Heart Lung and Circulation</i> , 2019, 28, 939-945.	0.2	11
54	A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1543-1556.	1.6	144

#	ARTICLE	IF	CITATIONS
55	Outcomes of anemic patients presenting with acute coronary syndrome: An analysis of the Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events. <i>Clinical Cardiology</i> , 2019, 42, 791-796.	0.7	8
56	Type-II myocardial infarction and chronic myocardial injury rates, invasive management, and 4-year mortality among consecutive patients undergoing high-sensitivity troponin T testing in the emergency department. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 6, 41-48.	1.8	7
57	Impact of patient's health-related quality of life on physicians' therapy and perceived benefit in acute coronary syndromes: protocol for a systemic review of quantitative and qualitative studies. <i>BMJ Open</i> , 2019, 9, e026595.	0.8	1
58	Evaluating recruitment strategies for AUSPICE, a large Australian community-based randomised controlled trial. <i>Medical Journal of Australia</i> , 2019, 210, 409-415.	0.8	12
59	Multidisciplinary transcatheter aortic valve replacement heart team programme improves mortality in aortic stenosis. <i>Open Heart</i> , 2019, 6, e000983.	0.9	21
60	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. <i>BMJ Open</i> , 2019, 9, e032165.	0.8	27
61	The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design. <i>American Heart Journal</i> , 2019, 208, 11-20.	1.2	49
62	TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: a randomised clinical trial protocol. <i>BMJ Open</i> , 2018, 8, e019463.	0.8	19
63	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 309-317.	1.8	12
64	Evaluation and management of patients with acute chest pain in China (EMPACT): protocol for a prospective, multicentre registry study. <i>BMJ Open</i> , 2018, 8, e017872.	0.8	8
65	Expertise and infrastructure capacity impacts acute coronary syndrome outcomes. <i>Australian Health Review</i> , 2018, 42, 277.	0.5	2
66	Socioeconomic Equity in the Receipt of In-Hospital Care and Outcomes in Australian Acute Coronary Syndrome Patients: The CONCORDANCE Registry. <i>Heart Lung and Circulation</i> , 2018, 27, 1398-1405.	0.2	6
67	Clinician assessment of acute coronary syndrome in the emergency department. <i>British Journal of Cardiac Nursing</i> , 2018, 13, 498-505.	0.0	0
68	Frailty and Outcomes After Myocardial Infarction: Insights From the CONCORDANCE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009859.	1.6	60
69	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. <i>European Heart Journal</i> , 2018, 39, 3798-3806.	1.0	62
70	Invasive management of acute coronary syndrome: Interaction with competing risks. <i>International Journal of Cardiology</i> , 2018, 269, 13-18.	0.8	10
71	Differences in management and outcomes for men and women with ST-elevation myocardial infarction. <i>Medical Journal of Australia</i> , 2018, 209, 118-123.	0.8	106
72	Outpatient heart failure programs: time for a new standard. <i>Medical Journal of Australia</i> , 2018, 208, 482-483.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Screening for important unwarranted variation in clinical practice: a triple-test of processes of care, costs and patient outcomes. Australian Health Review, 2017, 41, 104.	0.5	22
74	Suspected ACS Patients Presenting With Myocardial Damage or a Type 2 Myocardial Infarction Have a Similar Late Mortality to Patients With a Type 1 Myocardial Infarction: A Report From the Australian and New Zealand 2012 SNAPSHOT ACS Study. Heart Lung and Circulation, 2017, 26, 1051-1058.	0.2	2
75	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. International Journal of Cardiology, 2017, 240, 30-36.	0.8	15
76	Rational clinical evaluation of suspected acute coronary syndromes: The value of more information. EMA - Emergency Medicine Australasia, 2017, 29, 664-671.	0.5	1
77	A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID-TnT) study. American Heart Journal, 2017, 190, 25-33.	1.2	20
78	Cost effectiveness of high-sensitivity troponin compared to conventional troponin among patients presenting with undifferentiated chest pain: A trial based analysis. International Journal of Cardiology, 2017, 238, 144-150.	0.8	17
79	Predicting Risk in ACS. Journal of the American College of Cardiology, 2017, 70, 1858-1860.	1.2	2
80	Raising the bar on guideline utility and trustworthiness. Internal Medicine Journal, 2017, 47, 613-616.	0.5	0
81	Is There Inequity in Hospital Care Among Patients With Acute Coronary Syndrome Who Are Proficient and Not Proficient in English Language?. Journal of Cardiovascular Nursing, 2017, 32, 288-295.	0.6	8
82	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. International Journal of Cardiology, 2017, 244, 24-29.	0.8	19
83	A Comparison of Radial and Femoral Coronary Angiography in Patients From SNAPSHOT ACS, a Prospective Acute Coronary Syndrome Audit in Australia and New Zealand. Heart Lung and Circulation, 2017, 26, 258-267.	0.2	3
84	Has invasive management for acute coronary syndromes become more "risk-appropriate": pooled results of five Australian registries. European Heart Journal Quality of Care & Clinical Outcomes, 2017, 3, 133-140.	1.8	0
85	Pre-hospital thrombolysis in ST-segment elevation myocardial infarction: a regional Australian experience. Medical Journal of Australia, 2017, 206, 369-369.	0.8	0
86	Variation in coronary angiography rates in Australia: correlations with socio-demographic, health service and disease burden indices. Medical Journal of Australia, 2016, 205, 114-120.	0.8	18
87	English as a second language and outcomes of patients presenting with acute coronary syndromes: results from the CONCORDANCE registry. Medical Journal of Australia, 2016, 204, 239-239.	0.8	19
88	Clinical care standards: appropriate care everywhere " acute coronary syndromes as an example. Medical Journal of Australia, 2016, 205, S8-S11.	0.8	2
89	P2Y12 Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model. Journal of Clinical Medicine, 2016, 5, 72.	1.0	1
90	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Medical Journal of Australia, 2016, 205, 128-133.	0.8	112

#	ARTICLE	IF	CITATIONS
91	Instantaneous Decrease in Left Ventricular Afterload during Transcatheter Aortic Valve Implantation Results in Immediate Changes in Left Ventricular Strain. <i>Echocardiography</i> , 2016, 33, 742-748.	0.3	5
92	The household economic burden for acute coronary syndrome survivors in Australia. <i>BMC Health Services Research</i> , 2016, 16, 636.	0.9	5
93	Falling cholesterol trend at acute coronary syndrome presentation is strongly related to statin use for secondary prevention. <i>International Journal of Cardiology</i> , 2016, 212, 192-197.	0.8	3
94	Condition-specific Streaming versus an Acuity-based Model of Cardiovascular Care: A Historically-controlled Quality Improvement Study Evaluating the Association with Early Clinical Events. <i>Heart Lung and Circulation</i> , 2016, 25, 19-28.	0.2	2
95	Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). <i>American Heart Journal</i> , 2016, 177, 58-65.	1.2	33
96	International Mobile-Health Intervention on Physical Activity, Sitting, and Weight. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2453-2463.	1.2	81
97	Rewarming Temperature During Cardiopulmonary Bypass and Acute Kidney Injury: A Multicenter Analysis. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1655-1662.	0.7	40
98	Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995-2010. <i>International Journal of Cardiology</i> , 2016, 208, 19-25.	0.8	40
99	The relationship between the proportion of admitted high risk ACS patients and hospital delivery of evidence based care. <i>International Journal of Cardiology</i> , 2016, 222, 86-92.	0.8	3
100	Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 715-723.	1.2	79
101	Randomized Comparison of High-Sensitivity Troponin Reporting in Undifferentiated Chest Pain Assessment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 542-553.	0.9	27
102	Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1073.	3.8	80
103	National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. <i>Heart Lung and Circulation</i> , 2016, 25, 895-951.	0.2	222
104	Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). <i>American Journal of Medicine</i> , 2016, 129, 1307-1315.	0.6	5
105	Variation in Clinical Practice: A Priority Setting Approach to the Staged Funding of Quality Improvement. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 21-27.	1.0	12
106	Characteristics and Clinical Course of STEMI Patients who Received no Reperfusion in the Australia and New Zealand SNAPSHOT ACS Registry. <i>Heart Lung and Circulation</i> , 2016, 25, 132-139.	0.2	11
107	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. <i>American Journal of Cardiology</i> , 2016, 117, 754-759.	0.7	15
108	Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial. <i>American Heart Journal</i> , 2016, 174, 7-13.	1.2	3

#	ARTICLE	IF	CITATIONS
109	The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2016, 37, 1591-1602.	1.0	296
110	The predictive value of high sensitivity-troponin velocity within the first 6h of presentation for cardiac outcomes regardless of acute coronary syndrome diagnosis. <i>International Journal of Cardiology</i> , 2016, 204, 106-111.	0.8	11
111	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
112	Phase 4 Studies in Heart Failure - What is Done and What is Needed?. <i>Current Cardiology Reviews</i> , 2016, 12, 216-230.	0.6	18
113	Should fee-for-service be for all guideline-advocated acute coronary syndrome (ACS) care? Observations from the Snapshot ACS study. <i>Australian Health Review</i> , 2015, 39, 379.	0.5	3
114	The Heart Health Study - increasing cardiovascular risk assessment in family practice for first degree relatives of patients with premature ischaemic heart disease: a randomised controlled trial. <i>BMC Family Practice</i> , 2015, 16, 116.	2.9	3
115	Re-infarction after primary percutaneous coronary intervention. <i>Current Opinion in Cardiology</i> , 2015, 30, 354-358.	0.8	5
116	Survival after an acute coronary syndrome: 18-month outcomes from the Australian and New Zealand SNAPSHOT ACS study. <i>Medical Journal of Australia</i> , 2015, 203, 368-368.	0.8	26
117	The Clinical Care Standards in ACS: Towards an Integrated Approach to Evidence Translation in ACS Care. <i>Heart Lung and Circulation</i> , 2015, 24, 213-215.	0.2	7
118	Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events (CONCORDANCE). <i>American Heart Journal</i> , 2015, 170, 566-572.e1.	1.2	26
119	High sensitivity-troponin elevation secondary to non-coronary diagnoses and death and recurrent myocardial infarction: An examination against criteria of causality. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 419-428.	0.4	17
120	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). <i>American Heart Journal</i> , 2015, 170, 995-1004.e1.	1.2	23
121	Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN, a first-in-human study using a multi-electrode ablation system. <i>International Journal of Cardiology</i> , 2015, 201, 345-350.	0.8	31
122	Prognostic impact of moderate or severe mitral regurgitation (MR) irrespective of concomitant comorbidities: a retrospective matched cohort study. <i>BMJ Open</i> , 2014, 4, e004984-e004984.	0.8	22
123	Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand. <i>Heart</i> , 2014, 100, 1281-1288.	1.2	91
124	An examination of clinical intuition in risk assessment among acute coronary syndromes patients: Observations from a prospective multi-center international observational registry. <i>International Journal of Cardiology</i> , 2014, 171, 209-216.	0.8	34
125	A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. <i>European Journal of Epidemiology</i> , 2014, 29, 181-190.	2.5	99
126	Study design of embracing high-sensitivity troponin effectively: The value of more information: A randomized comparison. <i>Contemporary Clinical Trials</i> , 2014, 39, 183-190.	0.8	4



#	ARTICLE	IF	CITATIONS
127	Catheter-Based Renal Denervation for Resistant Hypertension. <i>Hypertension</i> , 2014, 64, 565-572.	1.3	65
128	Balloon aortic valvuloplasty to bridge and triage patients in the era of transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 358-363.	0.7	29
129	Coronary Artery Wall Thickness of the Left Anterior Descending Artery Using High Resolution Transthoracic Echocardiography – Normal Range of Values. <i>Echocardiography</i> , 2013, 30, 759-764.	0.3	19
130	Comparison of Three Risk Stratification Rules for Predicting Patients With Acute Coronary Syndrome Presenting to an Australian Emergency Department. <i>Heart Lung and Circulation</i> , 2013, 22, 844-851.	0.2	40
131	Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. <i>European Heart Journal</i> , 2013, 34, 2132-2140.	1.0	267
132	Intracoronary ECG during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction predicts microvascular obstruction and infarct size. <i>International Journal of Cardiology</i> , 2013, 165, 61-66.	0.8	17
133	Prognostic value of adenosine stress perfusion cardiac MRI with late gadolinium enhancement in an intermediate cardiovascular risk population. <i>International Journal of Cardiology</i> , 2013, 167, 2055-2060.	0.8	16
134	Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 299-308.	0.9	63
135	Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study. <i>Medical Journal of Australia</i> , 2013, 199, 185-191.	0.8	134
136	The management of acute coronary syndrome patients across New Zealand in 2012: results of a third comprehensive nationwide audit and observations of current interventional care. <i>New Zealand Medical Journal</i> , 2013, 126, 36-68.	0.5	17
137	The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: retrospective analysis study from the ACACIA registry. <i>BMJ Open</i> , 2012, 2, e000540.	0.8	72
138	Long-term antiplatelet therapy. <i>Current Opinion in Cardiology</i> , 2012, 27, 347-354.	0.8	1
139	Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 182-190.e4.	1.2	89
140	National Heart Foundation Response to Letter, “Ambiguous Cardiac Troponin Recommendations”. <i>Heart Lung and Circulation</i> , 2012, 21, 198.	0.2	1
141	Measuring performance and outcomes of acute coronary syndromes management in Australia. <i>Medical Journal of Australia</i> , 2012, 197, 140-142.	0.8	3
142	Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. <i>Medical Journal of Australia</i> , 2012, 196, 193-197.	0.8	13
143	Intracoronary ECG ST-segment recovery during primary percutaneous intervention for ST-segment myocardial infarction: Insights from a cardiac MRI study. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 746-753.	0.7	5
144	Predictors of Statin-Induced Regression of Left Anterior Descending Coronary Artery Wall Thickness as Measured by High-Resolution Transthoracic Echocardiography. <i>Echocardiography</i> , 2012, 29, 641-646.	0.3	2

#	ARTICLE	IF	CITATIONS
145	Promise of Factor Xa Inhibition in Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2012, 14, 40-48.	1.3	2
146	Simple or Complex Stenting for Bifurcation Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 57-64.	1.4	152
147	Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. <i>Heart Rhythm</i> , 2011, 8, 955-960.	0.3	88
148	2011 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand guidelines for the management of acute coronary syndromes (ACS) 2006. <i>Heart Lung and Circulation</i> , 2011, 20, 487-502.	0.2	103
149	Influence of metabolic syndrome on outcome after percutaneous coronary intervention. <i>Interventional Cardiology</i> , 2011, 3, 721-726.	0.0	3
150	Tissue Doppler Derived Mechanical Dyssynchrony Does Not Change after Cardiac Resynchronization Therapy. <i>Echocardiography</i> , 2011, 28, 961-967.	0.3	3
151	Lost in Translation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 512-520.	0.9	19
152	Intra-aortic Balloon Counterpulsation and Infarct Size in Patients With Acute Anterior Myocardial Infarction Without Shock. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1329.	3.8	348
153	Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. <i>Current Opinion in Cardiology</i> , 2010, 25, 305-311.	0.8	6
154	The role of antiplatelet therapy in the secondary prevention of coronary artery disease. <i>Current Opinion in Cardiology</i> , 2010, 25, 321-328.	0.8	14
155	Cost effectiveness of a general practice chronic disease management plan for coronary heart disease in Australia. <i>Australian Health Review</i> , 2010, 34, 162.	0.5	15
156	Treatment disparities and effect on late mortality in patients with diabetes presenting with acute myocardial infarction: observations from the ACACIA registry. <i>Medical Journal of Australia</i> , 2009, 191, 539-543.	0.8	18
157	Acute coronary syndromes: consensus recommendations for translating knowledge into action. <i>Medical Journal of Australia</i> , 2009, 191, 334-338.	0.8	29
158	Intravenous Platelet Blockade with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2330-2341.	13.9	560
159	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2318-2329.	13.9	533
160	Prognostic Impact of Types of Atrial Fibrillation in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2009, 104, 1317-1323.	0.7	125
161	Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with nona€ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. <i>American Heart Journal</i> , 2009, 157, 60.e1-60.e9.	1.2	17
162	Differences in Treatment and Management of Indigenous and Non-Indigenous Patients Presenting with Chest Pain: Results of the Heart Protection Partnership (HPP) Study. <i>Heart Lung and Circulation</i> , 2009, 18, 32-37.	0.2	11

#	ARTICLE	IF	CITATIONS
163	The Value of "More" Information: The Emerging Role of Novel Diagnostic Investigations in Cardiovascular Medicine. <i>Heart Lung and Circulation</i> , 2009, 18, 114-117.	0.2	0
164	Drug Treatment and Cost of Cardiovascular Disease in Australia. <i>Cardiovascular Therapeutics</i> , 2009, 27, 164-172.	1.1	14
165	Randomized trials of clinical networks in the management of ST-elevation MI: can they be performed?. <i>Current Opinion in Cardiology</i> , 2009, 24, 301-306.	0.8	6
166	Thinking styles and doctors' knowledge and behaviours relating to acute coronary syndromes guidelines. <i>Implementation Science</i> , 2008, 3, 23.	2.5	43
167	Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 639-648.	1.1	58
168	Changes in Left Anterior Descending Coronary Artery Wall Thickness Detected by High Resolution Transthoracic Echocardiography. <i>American Journal of Cardiology</i> , 2008, 101, 937-940.	0.7	9
169	Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1734-1741.	1.2	74
170	A Randomised Study of Three Different Informational Aids Prior To Coronary Angiography, Measuring Patient Recall, Satisfaction and Anxiety. <i>Heart Lung and Circulation</i> , 2008, 17, 25-32.	0.2	51
171	Australians at Risk: Management of Cardiovascular Risk Factors in the REACH Registry. <i>Heart Lung and Circulation</i> , 2008, 17, 114-118.	0.2	37
172	Cardiac MRI Assessment of Left and Right Ventricular Parameters in Healthy Australian Normal Volunteers. <i>Heart Lung and Circulation</i> , 2008, 17, 313-317.	0.2	23
173	The Last Mile: Improving Patient Outcomes within Modern Cardiovascular Medicine. <i>Heart Lung and Circulation</i> , 2008, 17, S10-S13.	0.2	2
174	Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. <i>American Heart Journal</i> , 2008, 155, 239-244.	1.2	9
175	Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. <i>American Heart Journal</i> , 2008, 155, 841-847.	1.2	18
176	Acute myocardial infarction. <i>Lancet, The</i> , 2008, 372, 570-584.	6.3	557
177	High-Resolution Transthoracic Echocardiography of the Left Anterior Descending Coronary Artery: A Novel Noninvasive Assessment of Coronary Vasoreactivity. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 134-138.	1.2	9
178	Assessment of early diastolic left ventricular function by two-dimensional echocardiographic speckle tracking. <i>European Journal of Echocardiography</i> , 2008, 9, 791-795.	2.3	25
179	Variations in the application of cardiac care in Australia. <i>Medical Journal of Australia</i> , 2008, 188, 218-223.	0.8	39
180	2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006. <i>Medical Journal of Australia</i> , 2008, 188, 302-303.	0.8	31

#	ARTICLE	IF	CITATIONS
181	Invasive management and late clinical outcomes in contemporary Australian management of acute coronary syndromes: observations from the ACACIA registry. <i>Medical Journal of Australia</i> , 2008, 188, 691-697.	0.8	76
182	Glycoprotein IIb/IIIa Inhibitors. , 2008, , 65-86.		2
183	Statin Therapy Alone and in Combination with an Acyl-CoA:Cholesterol &lt;i>O&lt;/i>-Acyltransferase Inhibitor on Experimental Atherosclerosis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 9-17.	0.5	10
184	Peroxisome proliferatorâ€“activated receptor Î³ agonists for the Prevention of Adverse events following percutaneous coronary Revascularizationâ€”results of the PPAR Study. <i>American Heart Journal</i> , 2007, 154, 137-143.	1.2	31
185	In Unstable Angina or Nonâ€“ST-Segment Acute Coronary Syndrome, Should Patients With Multivessel Coronary Artery Disease Undergo Multivessel or Culprit-Only Stenting?. <i>Journal of the American College of Cardiology</i> , 2007, 49, 849-854.	1.2	108
186	Predictors and Impact of Major Hemorrhage on Mortality Following Percutaneous Coronary Intervention from the REPLACE-2 Trial. <i>American Journal of Cardiology</i> , 2007, 100, 1364-1369.	0.7	315
187	QRS Duration Alone Misses Cardiac Dyssynchrony in a Substantial Proportion of Patients with Chronic Heart Failure. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 1257-1263.	1.2	31
188	Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with nonâ€“ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. <i>American Heart Journal</i> , 2006, 152, 1042-1050.	1.2	85
189	Bare metal stent restenosis is not a benign clinical entity. <i>American Heart Journal</i> , 2006, 151, 1260-1264.	1.2	367
190	Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)â€“2 trial. <i>American Heart Journal</i> , 2006, 151, 1032.e1-1032.e7.	1.2	37
191	Bivalirudin in percutaneous coronary intervention. <i>Vascular Health and Risk Management</i> , 2006, 2, 357-363.	1.0	12
192	Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). <i>American Journal of Cardiology</i> , 2005, 95, 581-585.	0.7	89
193	Renal failure after percutaneous coronary intervention is associated with high mortality. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 64, 442-448.	0.7	143
194	Facilitated percutaneous coronary intervention: Is this strategy ready for implementation?. <i>Current Cardiology Reports</i> , 2005, 7, 235-241.	1.3	2
195	Costâ€“effectiveness of drugâ€“eluting stents: if only all things were equal. <i>Medical Journal of Australia</i> , 2005, 182, 376-377.	0.8	11
196	Bivalirudin vs Heparin in Percutaneous Coronary Intervention: A Pooled Analysis. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 209-216.	1.0	33
197	The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. <i>American Heart Journal</i> , 2005, 150, 1190-1197.	1.2	17
198	Outcomes in African Americans and whites after percutaneous coronary intervention. <i>American Journal of Medicine</i> , 2005, 118, 1019-1025.	0.6	26

#	ARTICLE	IF	CITATIONS
199	Plasma Surfactant Protein-B. <i>Circulation</i> , 2004, 110, 1091-1096.	1.6	51
200	Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 2004, 93, 356-359.	0.7	104
201	Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 93, 679-684.	0.7	117
202	Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td Journal of Cardiology, 2004, 93, 1092-1096.	0.7	215
203	Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 94, 358-360.	0.7	100
204	Feasibility of simultaneous bilateral carotid artery stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 61, 437-442.	0.7	35
205	Meta-Analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. <i>Journal of the American College of Cardiology</i> , 2004, 43, 936-942.	1.2	109
206	Impact of female sex on outcome after percutaneous coronary intervention. <i>American Heart Journal</i> , 2004, 148, 998-1002.	1.2	36
207	Extracorporeal Elimination of Large Concentrations of Tirofiban by Zero-Balanced Ultrafiltration During Cardiopulmonary Bypass: An In Vitro Investigation. <i>Anesthesia and Analgesia</i> , 2004, 99, 989-992.	1.1	12
208	Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. <i>American Journal of Cardiology</i> , 2003, 91, 346-347.	0.7	16
209	Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomesâ€”observations from the TARGET trial. <i>American Journal of Cardiology</i> , 2003, 92, 125-129.	0.7	9
210	Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. <i>American Journal of Cardiology</i> , 2003, 92, 919-923.	0.7	92
211	Bivalirudin Monitored with the Ecarin Clotting Time for Anticoagulation During Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2003, 96, 383-386.	1.1	71
212	An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An In Vitro Study. <i>Anesthesia and Analgesia</i> , 2003, 96, 1316-1319.	1.1	57
213	Death Following Creatine Kinase-MB Elevation After Coronary Intervention. <i>Circulation</i> , 2002, 106, 1205-1210.	1.6	204
214	Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 777-788.	0.9	15
215	Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. <i>American Journal of Cardiology</i> , 2002, 89, 1209-1211.	0.7	28
216	Present and potential future paradigms for the treatment of ST-segment elevation acute myocardial infarction. <i>Journal of Invasive Cardiology</i> , 2002, 14 Suppl A, 3A-20A.	0.4	2

#	ARTICLE	IF	CITATIONS
217	Managing unstable angina in high-risk patients. <i>Journal of Invasive Cardiology</i> , 2002, 14 Suppl A, 31A-48A.	0.4	0
218	Oral Glycoprotein IIb/IIIa Inhibitors. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 421-428.	1.0	39
219	Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists. <i>Circulation</i> , 2001, 103, 201-206.	1.6	359
220	Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. <i>Current Cardiology Reports</i> , 2001, 3, 63-71.	1.3	13
221	Effect of Clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. <i>American Journal of Cardiology</i> , 2001, 88, 672-674.	0.7	144
222	Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery. <i>Circulation</i> , 2001, 103, 363-368.	1.6	266
223	Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non- $\sigma$ ST-Segment-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2001, 104, 2767-2771.	1.6	411
224	Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 104, 992-997.	1.6	241
225	Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 103, 961-966.	1.6	336